ArticleJournal of materials science. Materials in medicine2025
Biological applications on a novel composite hydrogel containing mesoporous silica nanoparticles loaded with insulin-like growth Factor-1 and Vancomycin.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multifunctional Nanomaterial-Integrated Hydrogels for Sustained Drug Delivery: From Synthesis and Characterization to Biomedical Application.Gels (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Polymer nanocomposites have prolific applications in the environmental and health domain. Healthcare workers have constantly faced a challenge in constructing an effective sustained-release system for drugs, especially in areas where it is difficult to follow traditional treatment guidelines. To achieve a dual sustained release of vancomycin and cell growth factors, we designed a composite hydrogel, which was polymerized under ultraviolet irradiation to form a methacrylate gelatin (GelMA)/polyethylene glycol diacrylate (PEGDA) cross-linked system. The hydrogel showed antibacterial and pro-osteogenic differentiation activities by blending it with vancomycin and insulin-like growth factor 1 (IGF-1)-loaded silica particles. The experimental results showed that with increased PEGDA concentration, the hydrogels were degraded by swelling with a longer sustained release time. After 144-h immersion, the hydrogel still showed sustained release of IGF-1. The antibacterial experiment showed that the hydrogel pair had an obvious antibacterial effect against S. aureus. The results of live/dead staining and Cell Counting kit-8 assay indicated excellent biocompatibility of the hydrogel. Alizarin Red staining (ARS) further demonstrated that this hydrogel could induce bone marrow stem cells to initiate osteogenic differentiation. This hydrogel material exhibited excellent antibacterial and pro-osteogenic differentiation properties and might be promising for chronic osteomyelitis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.